P4‐472: Vasogenic edema in the setting of ß‐amyloid lowering therapy, adverse event: what is it and how is it detected?
Jerome Barakos(Sutter Health), Eric Siemers(Eli Lilly (United States)), Wahiba Estergard(Eli Lilly (United States)), Joyce Suhy(BioClinica (United States)), Clifford R. Jack(Mayo Clinic), Joonmi Oh(Biogen (United States)), Christopher Carlson(Eli Lilly (United States))
Cited by 3
Related Papers
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|18.9k
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.3k